Ghosh Anita, Hellewell Jonathan S E
Trafford General Hospital, Moorside Road, Urmston, Manchester, Greater Manchester, M41 5SL, UK.
Expert Opin Investig Drugs. 2007 Dec;16(12):1999-2004. doi: 10.1517/13543784.16.12.1999.
Agomelatine is a novel agent that is under late-stage development as a potential antidepressant. Compared with available antidepressant agents, the drug may have a distinct mechanism of action, with significant interactions with melatonin receptors, in addition to serotonergic brain systems. Agomelatine has been shown to be active in preclinical models indicative of antidepressant activity and the results of a large-scale clinical trial programme, conducted in major depressive disorder, indicate both antidepressant activity and a favourable tolerability profile. As agomelatine may have a pharmacological profile and mechanism of action distinct from available agents, it may come to represent a valuable additional treatment option in those patients who do not respond fully or who prove unable to tolerate the side effects of existing antidepressants.
阿戈美拉汀是一种处于后期研发阶段的新型潜在抗抑郁药。与现有的抗抑郁药相比，该药物可能具有独特的作用机制，除了与血清素能脑系统相互作用外，还与褪黑素受体有显著相互作用。阿戈美拉汀在表明具有抗抑郁活性的临床前模型中已显示出活性，在重度抑郁症中进行的大规模临床试验项目结果表明其具有抗抑郁活性和良好的耐受性。由于阿戈美拉汀可能具有与现有药物不同的药理学特征和作用机制，它可能成为那些对现有抗抑郁药反应不完全或无法耐受其副作用的患者的一种有价值的额外治疗选择。
